The Banking segment focuses on the preservation of umbilical cord blood, cord lining, and cord tissue. This involves the collection, processing, and cryopreservation of stem cells derived from these sources. Cordlife employs advanced cell processing technologies to maximize stem cell recovery and viability. These stem cells are stored under stringent conditions for potential future use in regenerative medicine and transplantation therapies. The segment addresses the growing demand for personalized healthcare solutions and offers families the opportunity to secure a readily available source of stem cells for potential therapeutic applications. Research efforts are directed towards optimizing storage protocols and expanding the range of treatable conditions using cord blood-derived stem cells. The banking segment positions Cordlife as a key player in the regenerative medicine landscape, offering a valuable service to families seeking long-term health security.

The Diagnostics segment provides a range of screening and diagnostic services focused on maternal and newborn health. This includes non-invasive prenatal testing (NIPT) to screen for chromosomal abnormalities in the fetus, as well as newborn metabolic and genetic screening to identify potential health risks early in life. Cordlife utilizes advanced genomic technologies and molecular diagnostic techniques to ensure accurate and reliable results. The segment also offers paediatric vision screening and genetic talent tests. Research and development efforts are focused on expanding the diagnostic test menu and improving the accuracy and efficiency of existing tests. By providing early detection and risk assessment, the Diagnostics segment enables timely intervention and personalized care, improving health outcomes for mothers and children. This segment positions Cordlife as a comprehensive provider of essential healthcare services for families, contributing to proactive and preventative healthcare management.